

**Fusion of
Biological
Membranes and
Related Problems**

Subcellular Biochemistry

Volume 34

SUBCELLULAR BIOCHEMISTRY

SERIES EDITOR

J. ROBIN HARRIS, Institute of Zoology, University of Mainz, Mainz, Germany

ASSISTANT EDITORS

H. J. HILDERSON, University of Antwerp, Antwerp, Belgium

B. B. BISWAS, University of Calcutta, Calcutta, India

Recent Volumes in This Series

- Volume 25 **Ascorbic Acid: Biochemistry and Biomedical Cell Biology**
 Edited by J. Robin Harris
- Volume 26 ***myo*-Inositol Phosphates, Phosphoinositides, and Signal Transduction**
 Edited by B. B. Biswas and Susweta Biswas
- Volume 27 **Biology of the Lysosome**
 Edited by John B. Lloyd and Robert W. Mason
- Volume 28 **Cholesterol: Its Functions and Metabolism in Biology and Medicine**
 Edited by Robert Bittman
- Volume 29 **Plant–Microbe Interactions**
 Edited by B. B. Biswas and H. K. Das
- Volume 30 **Fat-soluble Vitamins**
 Edited by Peter J. Quinn and Valerian E. Kagan
- Volume 31 **Intermediate Filaments**
 Edited by Harald Herrmann and J. Robin Harris
- Volume 32 **α -Gal and Anti-Gal; α 1,3-Galactosyltransferase, α -Gal Epitopes, and the Natural Anti-Gal Antibody**
 Edited by Uri Galili and José Luis Avila
- Volume 33 **Bacterial Invasion into Eukaryotic Cells**
 Edited by Tobias A. Oelschlaeger and Jörg Hacker
- Volume 34 **Fusion of Biological Membranes and Related Problems**
 Edited by Herwig Hilderson and Stephen Fuller

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

Fusion of Biological Membranes and Related Problems

Subcellular Biochemistry
Volume 34

Edited by

Herwig Hilderson

*University of Antwerp
Antwerp, Belgium*

and

Stephen Fuller

*European Molecular Biology Laboratory
Heidelberg, Germany*

Kluwer Academic Publishers
New York, Boston, Dordrecht, London, Moscow

eBook ISBN: 0-306-46824-7
Print ISBN: 0-306-46313-X

©2002 Kluwer Academic Publishers
New York, Boston, Dordrecht, London, Moscow

All rights reserved

No part of this eBook may be reproduced or transmitted in any form or by any means, electronic, mechanical, recording, or otherwise, without written consent from the Publisher

Created in the United States of America

Visit Kluwer Online at: <http://www.kluweronline.com>
and Kluwer's eBookstore at: <http://www.ebooks.kluweronline.com>

INTERNATIONAL ADVISORY EDITORIAL BOARD

J. L. AVILA, Instituto de Bionedecina, Caracas, Venezuela
R. BITTMAN, City University of New York New York, USA
N. BORGESE, CNR Center for Cytopharmacolgy, University of Milan, Milan, Italy
D. DASGUPTA, Saha Institute of Nuclear Physics, Calcutta, India
H. ENGELHARDT, Max-Planck-Institute for Biochemistry Martinsried Germany
A-H. ETÉMADI, University of Paris VI, Paris, France
S. FULLER, European Molecular Biology Laboratory, Heidelberg Germany
J. HACKER, University of Würzburg Würzburg Germany
H. HERRMANN, German Cancer Research Center, Heidelberg, Germany
A. HOLZENBURG University of Leeds, Leeds, England UK
J. B. LLOYD, University of Sunderland, Sunderland England, UK
P. QUINN, King's College London, London England, UK
S. ROTTEM, The Hebrew University Jerusalem Israel

Contributors

Tina Ballegaard Institute of Biochemistry, Odense University, 5230 Odense M, Denmark

Pad N. Black Department of Biochemistry and Molecular Biology, Albany Medical College, Albany, New York 12208

Ineke Braakman Department of Biochemistry, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands

Prodyot K. Chatterjee Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, New York 10461

Philippe Collas Institute of Medical Biochemistry University of Oslo, PO Box 1112 Blindern, 0317 Oslo, Norway

Hilde De Busser RUCA-Laboratory for Human Biochemistry, Department of Biochemistry, Physiology and Genetics, University of Antwerp, B-2020 Antwerp, Belgium

Werner P. De Potter UIA Laboratory for Neuropharmacology Department of Medicine, University of Antwerp, B-2610 Wilrijk-Antwerp, Belgium

Concetta DiRusso Department of Biochemistry and Molecular Biology, Albany Medical College, Albany, New York 12208

Ben Distel Department of Biochemistry Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands

Robert W. Doms Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

- Ype Elgersma** University of California at Los Angeles, Department of Neurobiology, Los Angeles, California 90095
- Joakim Faergeman** Department of Biochemistry and Molecular Biology, Albany Medical College, Albany, New York 12208
- Dieter Gallwitz** Department of Molecular Genetics, Max-Planck-Institute for Biophysical Chemistry, Am Fassberg, D-37077 Göttingen, Germany
- Yves Gaudin** Laboratoire de Génétique des Virus, CNRS, 91198 Gif sur Yvette Cedex, France
- Don L. Gibbons** Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, New York 10461
- Martin Götte** Department of Molecular Genetics, Max-Planck-Institute for Biophysical Chemistry, Am Fassberg, D-37077 Göttingen, Germany
- Cordula Harter** Biochemie-Zentrum Heidelberg, Ruprecht-Karls-Universität, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany
- Catherine L. Jackson** Division of Biochemistry and Molecular Genetics, Department of Cellular and Molecular Biology, SBGM, Bat 142, CEA/Saclay, F-91191 Gif-sur-Yvette Cedex, France
- Margaret Kielian** Department of Cell Biology, Albert Einstein College of Medicine, 1300 Moms Park Ave., Bronx, New York 10461
- Jens Knudsen** Institute of Biochemistry, Odense University, 5230 Odense M, Denmark
- Helmut Kubista** Department of Physiology, University College London, Gower Street, London WC1E 6BT, United Kingdom
- Albert Lagrou** RUCA-Laboratory for Human Biochemistry, Department of Biochemistry, Physiology and Genetics, University of Antwerp, B-2020 Antwerp, Belgium
- Thomas Lazar** Department of Molecular Genetics, Max-Planck-Institute for Biophysical Chemistry, Am Fassberg, D-37077 Göttingen, Germany
- Michal Linial** Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University, Jerusalem, 91904 Israel
- Yanping E. Lu** Department of Cell Biology, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, New York 10461

- Carrie M. McManus** Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104
- Stephen Moss** Department of Physiology, University College London, Gower Street, London WC1E 6BT, United Kingdom
- Peter Partoens** UIA-Laboratory for Neuropharmacology, Department of Medicine, University of Antwerp, B-2610 Wilrijk-Antwerp, Belgium
- Dominic Poccia** Department of Biology, Amherst College, Amherst, Massachusetts 01002
- Constanze Reinhard** Biochemie-Zentrum Heidelberg, Ruprecht-Karls-Universität, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany
- Sandra Sacre** Department of Physiology, University College London, Gower Street, London WC1E 6BT, United Kingdom
- David Sanders** Department of Biological Sciences, Purdue University, West Lafayette, Indiana 47907
- Dietrich Scheglmann** Department of Molecular Genetics, Max-Planck-Institute for Biophysical Chemistry, Am Fassberg, D-37077 Göttingen, Germany
- Dirk Slembrouck** UIA Laboratory for Neuropharmacology, Department of Medicine, University of Antwerp, B-2610 Wilrijk-Antwerp, Belgium
- Henk F. Tabak** Department of Biochemistry, Academic Medical Center, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands
- Guido Van Dessel** UIA-Laboratory for Pathological Biochemistry, Department of Medicine, University of Antwerp, B-2020 Antwerp, Belgium
- Peter F. T. Vaughan** Institute for Cardiovascular Research, University of Leeds, Leeds LS2 9JT, United Kingdom
- Jin-San Yoo** Department of Molecular Genetics, Max-Planck-Institute for Biophysical Chemistry, Am Fassberg, D-37077 Göttingen, Germany

Preface

Membrane fusion and targeting processes are tightly regulated and coordinated. Dozens of proteins, originating from both the cytoplasm and membranes are involved. The discovery of homologous proteins from yeast to neurons validates a unified view.

Although much is known about the interfering proteins, the events occurring when two lipid bilayers actually fuse are less clear. One cannot exclude that lipid bilayers behave like soap-bubbles fusing when meeting each other. In this respect interfering proteins should be considered as preventing undesirable and unnecessary fusion and eventually directing the biological membrane fusion process (when, where, how and overcoming the activation energy).

In this volume of the series *Subcellular Biochemistry* some aspects of fusion of biological membranes as well as related problems are presented. Although not complete, one will find a lot of recent information including on virus-induced membrane fusion. The contributors of the chapters are all among the researchers who performed many of the pioneering studies in the field.

A first glance to the subject is found in *Chapter 1*, written by Cardula Harter and Constanze Reinhard. They give an overview of the route of a protein along the secretory pathway and summarize the progress that was made within the last decades. They discuss the current models for the formation and fusion of vesicular carriers with a major focus on the mechanism underlying budding of a COPI-coated vesicle.

In *Chapter 2* Michal Linial describes how neurotoxins (α -Latroxin and Clostridial toxins) can be used as tools in dissecting the exocytic machinery. The mode of action of α -Latroxin (inducing massive and uncontrolled vesicular release of neurotransmitters and neuropeptides) is still not

known. The effect of Clostridial toxins (blocking neurotransmitter release causing neuromuscular paralysis) on exocytosis can be explained by their activities on the SNAREs. According to the author, structural information on SNARE and on their associated proteins should be evaluated in view of the biophysics and kinetic properties of fusion. Therapeutic applications are described.

The role of annexins (a distinct family of Ca^{2+} -binding proteins) in vesicular traffic and membrane fusion events in exocytosis and endocytosis is discussed by Helmut Kubista, Sandra Sacre and Stephen Moss in *Chapter 3*. The authors state that many of the properties involved in NSF, SNAPs, SNAREs-dependent vesicle transport and membrane fusion machinery are shared by annexins. It is possible that annexins provide a specialized exocytotic pathway that works in parallel to other mechanisms, such as NSF-dependent exocytosis. Alternatively, some data suggest that annexins may function together with the NSF, SNAPs and SNARE-machinery. Some annexins are membrane fusogens, others may be involved in transport to and aggregation of vesicles at fusion sites, in regulation of the cytoskeleton at these sites, in organization of fusion membranes, in regulation of other annexins and in Ca^{2+} signaling.

In *Chapter 4* Martin Götte *et al.* show how the entire information of baker's yeast *Saccharomyces cerevisiae* genome is now known and freely accessible. All membrane fusion in eukaryotic cells is governed by a class of monomeric GTP-binding proteins, called Rab in mammals and Ypt in yeast. After a brief introduction to the Ras-superfamily the reader is familiarized with the structural features and posttranslational modifications common to all Ypt proteins. The functional cycling and the various states of Ypt proteins as well as the proteins known to interact with the Ypt GTPases are discussed. Current models of the function of every single member of the Ypt proteins in the vesicular transport are reviewed (Ypt1p, Yp31p, Ypt32p, Sec4p for exocytic and Ypt51p, Ypt52p, Ypt53p, Ypt7p for vacuolar and endocytic trafficking). The authors conclude that three Ypt GTPases (Ypt1p, Ypt3p, Sec4p) suffice in regulating trafficking from the ER to the plasma membrane, while three proteins (Ypt51p, Ypt6p, Ypt7p) mediate vesicular transport on the endocytic pathway.

In *Chapter 5* Nils Faergeman *et al.* highlight the numerous effects of long-chain fatty acyl-CoA esters (through partitioning into membranes, acyl-CoA-dependent remodeling in vesicle trafficking or reversible acylation of proteins) as cofactors for the fission and fusion of biomembranes. The significance of these effects is discussed in relation to the physiological concentration of long-chain fatty acyl-CoA esters and their binding proteins.

Brefeldin A (BFA) is known to prevent association of ARF to Golgi membranes and to inhibit secretion. In *Chapter 6* Catherine Jackson

discusses the early work describing the effects of BFA at both morphological and molecular levels. Next she introduces the family of Sec7 domain ARF exchange factors, and discusses the studies showing that they are major targets of BFA both *in vitro* and *in vivo*. The implications of the recently elucidated mechanism of action of BFA on Sec7 domain ARF exchange factors in transport through the ER-Golgi system are reviewed. Finally the author places ARF and its regulators into a model for ER-through-Golgi transport that takes into consideration the diverse *in vivo* effects of BFA.

The membrane fusion events during nuclear envelope assembly is reviewed by Philippe Collas and Dominic Poccia in *Chapter 7*. Several issues are addressed, including the multistep assembly of the nuclear envelope (from nuclear vesicles), the biochemical requirements for fusion of nuclear vesicles, evidence for the involvement of small GTPases in nuclear vesicle fusion, analogies between nuclear vesicle fusion and fusion events in intracellular membrane trafficking, the controversial role of Ca^{2+} in nuclear envelope assembly and evidence that some nuclear vesicles may harbor specific fusogenic elements.

A genetic approach to study the various processes involved in the maintenance, biosynthesis and proliferation of peroxisomes, creating a wealth of new ideas and information, experimental tools and mutants are discussed in *Chapter 8* by Ben Distel *et al.*

Neurons, chromaffin cells and membrane fusion are the subject of *Chapter 9*, the result of the collaboration between three different research groups (Hilde De Busser *et al.*; Peter Partoens *et al.*; Peter Vaughan). The authors limit themselves to a description of the membrane composition of the large dense-cored vesicles (LDVs)/secretory granules from which it can be concluded that the crucial actors governing small synaptic vesicles (SSVs) exocytosis are also responsible for LDV exocytosis. Subsequently they emphasize the role of the cytoskeleton in the exocytosis of LDVs and the role of GTP-binding proteins. Finally the related isoprenylating and carboxymethylating mechanisms are highlighted.

Yves Gaudin describes in *Chapter 10* how rhabdovirus-induced membrane fusion is an exception to the rule that the fusogenic protein in most cases of virus-plasma membrane fusion is synthesized in a metastable conformation, using the energy released during the fusogenic structural transition to achieve the energetically expensive membrane-fusion reaction. For rhabdoviruses the low pH-induced structural transition is absolutely reversible. A plausible role for the fusion inactive state is to avoid undesirable fusion in the acidic Golgi vesicles during the transport of fusogenic glycoprotein. The reversibility would be necessary for the protein being incorporated in a native functional conformation in neosynthesized virions.

The specific roles for lipids in virus fusion and exit is discussed by Margaret Kielian in *Chapter 11* using alphaviruses as an example. An efficient alphavirus exit requires the virus spike and nucleocapsid, the specific interaction of the E2 tail with nucleocapsid, the expression of 6K and correct lateral spike proteins interactions. In order to understand the roles played by cholesterol (entry, exit) and sphingolipids (hemifusion, complete fusion) in the alphavirus lifecycle (by interacting with viral proteins promoting fusogenic conformational changes) the current molecular understanding of alphavirus membrane fusion is discussed in detail. At the end of the article the author considers the available data suggesting a specific role of lipids in the entry and exit of other viruses and pathogens.

Chapter 12 is devoted to the fusion mediated by the HIV-1 envelope protein. In this chapter Carrie McManus and Robert Doms discuss the current understanding of the viral (Env, Gp120, Gp41) and cellular components (CD4, major and alternative HIV-1 coreceptors) necessary for the viral entry process. The identification of the HIV coreceptors coupled with detailed structural information on CD4, gp120 and gp41 has suggested several new anti-viral approaches. In addition to the coreceptors, Env itself can be targeted. Triggered or partially triggered Env proteins may elicit antibodies to highly conserved but poorly immunogenic domains that are competent to neutralize diverse virus isolates.

In the last chapter (*Chapter 13*) David Sanders shows how sulfhydryl groups are involved in fusion mechanisms. Cysteine is a special residue because it is sensitive to the oxidation/reduction potential of its environment. The author states that proteins promoting intracellular membrane fusion reside in the reducing environment of the cytoplasm, whereas those participating in membrane fusion between enveloped viruses and cells or between two or more cells are exposed to an oxidizing milieu. Following discussion of protein thiols in cellular membrane fusion and in viral-glycoprotein-mediated membrane fusion and virus entry, the author reconsiders the alphavirus entry, incorporating both acidified endosomes and thiol-disulfide exchange.

Finally, we would like to thank Paul Van Dyck for assisting in preparation of this book.

We wish all of you much enthusiasm and pleasure in reading the book.

Antwerp, Belgium
Heidelberg, Germany

Herwig Hilderson
Steve Fuller

Contents

Chapter 1

The Secretory Pathway: From History to the State of the Art

Cordula Harter and Constanze Reinhard

1. Summary	1
2. Definition of the Secretory Pathway	2
2.1. Discovery	2
2.2. Stations of the Secretory Pathway	3
2.2.1. Endoplasmic Reticulum	3
2.2.2. ER-Golgi Intermediate Compartment	3
2.2.3. The Golgi Apparatus	4
3. Transport through the Secretory Pathway	5
3.1. Export from the ER	6
3.1.1. COPII-Coated Vesicles	6
3.2. Transport into and through the Golgi	9
3.2.1. COPI-Coated Vesicles	9
3.3. Sorting at the <i>trans</i> -Golgi Network	12
3.3.1. Clathrin-Coated Vesicles	13
3.4. Recycling Pathways	14
3.5. Membrane Proteins in Vesicle Formation and Cargo Selection	15
3.5.1. Membrane Proteins of COP-Coated Vesicles ...	15
3.5.2. Membrane Proteins of Clathrin-Coated Vesicles	17
4. Mechanism of Vesicle Formation: Insights from the COPI System	18

- 4.1. Bivalent Interaction of Coatomer 18
- 4.2. Reconstitution of Coated Vesicles from Chemically Defined Liposomes 19
- 4.3. Polymerization of Coatomer and COPI Bud Formation 20
- 5. Mechanism of Vesicle Fusion 20
 - 5.1. SNARE Proteins 21
 - 5.2. NSF 23
 - 5.3. Additional Proteins Involved in Vesicle Fusion 24
 - 5.3.1. Targeting Proteins 24
 - 5.3.2. Modulators of SNARE Action 25
- 6. Perspectives 26
- 7. References 27

Chapter 2

Neurotoxins as Tools in Dissecting the Exocytic Machinery

Michal Linial

- 1. Introduction 39
 - 1.1. The Core of the Exocytic Machinery—the SNAREs 39
 - 1.2. Direct Associates of SNAREs 40
 - 1.3. Dynamic View of Secretion 42
- 2. Latrotoxin and Related Toxins 44
 - 2.1. Biology of the Toxins—Cell Recognition 44
 - 2.2. Structure and Biochemical Properties 45
- 3. Clostridial Toxins 47
 - 3.1. Biology of the Toxins—Cell Recognition and Activation 47
 - 3.2. Structure and Biochemical Properties 49
- 4. Investigating Secretion with Clostridial Toxins—The Methodologies 52
 - 4.1. *In vivo*—Genetic Approach 52
 - 4.2. *In vitro*—Tissues and Cells 53
 - 4.3. *In vitro*—Overexpressed Proteins 55
- 5. Clostridial Toxins as Molecular Probes for Secretion 57
 - 5.1. Probes for Evolutionary Conservation and Diversity 57
 - 5.2. Probes for Structural Specificity 58
 - 5.3. Identifying New SNAREs, Their Associates and Their Roles 60
 - 5.4. Studying the Diversity of Secretory Systems 61

6. Clostridial Toxins as Therapeutic Tools	62
6.1. A Clinical Perspective	62
6.2. In Model Systems	62
7. Future Perspective	63
8. References	63

Chapter 3

Annexins and Membrane Fusion

Helmut Kubista, Sandra Sacre, and Stephen E . Moss

1. Introduction	73
2. Annexins in Membrane Fusion	74
2.1. The Structural Basis of Annexin-Membrane Interactions	74
2.2. Modulation of Annexin-Membrane Interactions by Phosphorylation	80
2.3. Annexins and Membrane Fusion in Exocytosis	81
2.3.1. A Membrane Fusion Protein Activated by Ca ²⁺ , GTP and Protein Kinase C	82
2.3.2. Docking of Secretory Granules to the Plasma Membrane by Annexins	83
2.3.3. Annexins and Vesicle Aggregation	84
2.3.4. Annexins and the Organization of Membrane Microdomains	85
2.3.5. Annexins as Membrane Fusogens	87
2.3.6. Annexin-Mediated Ion Fluxes in Exocytosis	88
2.3.7. Annexin Binding to Secretory Regulators	90
3. Annexins and Membrane Fusion in Endocytosis	90
3.1. Annexin VI	92
3.2. Annexin II	96
3.3. Annexin I	98
4. Phagocytosis	100
4.1. Association of Annexins with Phagosomes	102
4.2. Annexin I and Phagocytosis in Neutrophils and Macrophages	103
4.3. The Annexin Family in Neutrophil Phagocytosis	106
5. Annexins in Regulated Exocytosis	107
5.1. Annexins from Simple Organisms	107
5.2. Annexin I in Exocytosis	107
5.3. Annexin II in Exocytosis	108

5.4.	Annexin III in Exocytosis	110
5.5.	Annexin V in Exocytosis	110
5.6.	Annexin VI in Exocytosis	111
5.7.	Annexin VII in Exocytosis	111
5.8.	Annexin XIII in Exocytosis	112
6.	Evidence against a Role for Annexins in Vesicle Trafficking	113
7.	Annexins: Fusogenic or Non-Fusogenic	113
8.	Conclusion and Outlook	118
9.	References	121

Chapter 4

The Full Complement of Yeast Ypt/Rab-GTPases and Their Involvement in Exo- and Endocytic Trafficking

Martin Götte, Thomas Lazar, Jin-San Yoo, Dietrich Scheglmann,
and Dieter Gallwitz

1.	Introduction	133
2.	The Ras-Superfamily	135
3.	The Ypt Protein: Structure	136
4.	The GTPase Cycle	139
5.	Ypt GTPases and SNAREs: The Fusion Machinery	142
6.	The Ypt Family One by One	145
6.1.	Ypt1p	145
6.2.	Ypt31p/Ypt32p	147
6.3.	Sec4p	148
6.4.	Ypt51p/Ypt52p/Ypt53p	150
6.5.	Ypt7p	152
6.6.	Ypt6p	153
6.7.	Ypt10p	155
6.8.	Ypt11p	156
7.	How Few Ypt GTPases Are Enough?	157
7.1.	Essential and Nonessential Ypt GTPases	157
7.2.	Redundancy among Ypt GTPases	158
7.3.	Ypt GTPases and Vesicular Trafficking Routes	159
8.	References	162

*Chapter 5***Possible Roles of Long-chain Fatty Acyl-CoA Esters in the Fusion of Biomembranes**

Nils Joakim Faergeman, Tina Ballegaard, Jens Knudsen,
Paul N. Black, and Concetta DiRusso

1. Introduction	175
2. Biophysical Properties of Long-chain Fatty Acyl-CoA Esters and Their Interaction with Biomembranes	178
3. Vesicle Trafficking	179
3.1. Assembly of Transport Vesicles	179
3.2. Fusion of Transport Vesicles	181
4. Long-chain Fatty Acyl-CoA Esters as Cofactors for Vesicles Budding and Fusion	188
4.1. Palmitoylation of Proteins Involved in Membrane Trafficking	190
4.2. The Enzymology of Protein Palmitoylation	193
4.3. Palmitoylation and Membrane Fusion, Similarities Between Influenza Virus Hemagglutinin and SNAREs	195
4.4. A Putative Link Between Coat Assembly, Phospholipases, Protein Kinases and Acyl-CoA Esters	198
5. Acyl-CoA-Dependent Lipid Remodeling in Vesicle Trafficking	199
5.1. Acyl-CoA and Vesicle Trafficking, Lessons from Yeast Mutants	200
6. Allosteric Effects of Long-chain Acyl-CoA on Vesicle Trafficking	202
6.1. Acyl-CoA Regulation of Ion Fluxes	202
7. Intracellular Acyl-CoA Binding Proteins	203
7.1. Acyl-CoA Binding Protein	203
7.2. Fatty Acid Binding Protein and Sterol Carrier Protein-2 in Acyl-CoA Metabolism	205
8. <i>In Vivo</i> Regulation of Long-chain Acyl-CoA Esters	207
8.1. Regulation of the Intracellular Acyl-CoA Concentration	207
9. Regulation of Vesicle Trafficking <i>In Vivo</i> by Long-chain Acyl-CoA Esters	211
10. References	213

*Chapter 6***Brefeldin A: Revealing the Fundamental principles Governing Membrane Dynamics and Protein Transport**

Catherine L. Jackson

1. Introduction	233
2. The Morphological Basis of Transport in the ER-GOLGI System	235
2.1. The Classic Models: Anterograde Vesicular Transport and Cisternal Maturation	235
2.2. The Three-Dimensional Structure of Intracellular Organelles and the Concept of Membrane Transformation	236
2.3. Regulated Forward Membrane Flux as the Driving Force for Anterograde Transport in the Exocytic Pathway	238
3. Morphological and Biochemical Effects of BFA	242
3.1. Early Studies of the Effects of BFA on the Secretory Pathway in Mammalian Cells	242
3.2. Conflicting Reports: Does the Golgi Disappear or Not?	243
3.3. The Effects of BFA in Yeast	245
3.4. The Effects of BFA on the Endocytic Pathway and Lysosomes: Fusion of Organelles within Systems and Traffic Jams	246
3.5. A Model to Explain the Morphological Effects of BFA	247
4. Molecular Effects of BFA	249
4.1. BFA Causes the Rapid Release of the COPI Coat from Golgi Membranes	249
4.2. BFA Inhibits Guanine Nucleotide Exchange on ARF	250
4.3. BFA Causes the Release of Many Golgi-Associated Proteins from Membranes	251
5. The Sec7 Domain Family of ARF Guanine Nucleotide Exchange Factors	253
5.1. Identification of Sec7 Domain Proteins as ARF Exchange Factors	253
5.2. Different Sec7 Domain Proteins have Different Sensitivities to BFA	256

5.3. Mechanism of Action of BFA: Stabilization of an Abortive ARF-GDP-Sec7 Domain Protein Complex	257
6. Conclusion	260
7. References	263

Chapter 7

Membrane Fusion Events during Nuclear Envelope Assembly

Philippe Collas and Dominic Poccia

Introduction: The Nuclear Envelope Is a Dynamic Structure	273
1. Assembly of the Nuclear Envelope Is a Multistep Process ...	275
1.1. Nuclear Reconstitution in Cell-Free Systems as Tools to Study Nuclear Envelope Assembly	275
1.2. Targeting and Binding of Nuclear Vesicles to Chromatin	277
1.3. Role of Lipophilic Structures (LSs) in Membrane Vesicle Binding to Chromatin	278
1.4. Distinct Membrane Vesicle Populations Contribute to the NE	279
2. Fusion of Nuclear Vesicles	281
2.1. Sealing and Growth of the Nuclear Envelope	281
2.1.1. Fusion of the Bulk of Nuclear Vesicles	281
2.1.2. LS-Vesicle Fusion	282
2.2. A Retrograde Vesicular Transport Mechanism Implicated in Nuclear Vesicle Targeting to Chromatin and Fusion?	283
2.3. Assays for Nuclear Vesicle Fusion	283
2.3.1. Fluorescence Evidence of Fusion	283
2.3.2. Exclusion of High Molecular Weight Dextran from Nuclei	284
2.3.3. Electron Microscopic Assays to Monitor Nuclear Vesicle Fusion	284
2.4. Cytosolic and Nucleotide Requirements for Nuclear Vesicle Fusion	287
3. Involvement of Small GTP-Binding Proteins in Nuclear Vesicle Dynamics	288
3.1. Nuclear Vesicle Fusion Requires GTP Hydrolysis	288
3.2. Early Evidence for a Putative Role of ARFs in Nuclear Vesicle Dynamics	288

3.3. Evidence for a Non-ARF GTPase Active in Nuclear Envelope Assembly	289
4. Analogies Between Nuclear Vesicle Fusion and Fusion Events in Intracellular Membrane Trafficking	290
4.1. Inhibition of Nuclear Vesicle Fusion with the Sulphydryl Modifier, <i>N</i> -Ethylmaleimide	290
4.2. Targeted Membrane Fusion Orchestrated by Components of the SNARE Hypothesis	291
4.3. A Role for p97 in Nuclear Envelope Assembly?	291
4.4. Implication of SNAREs in Nuclear Vesicle Targeting and Fusion: An Argument	292
5. A Role of Nuclear Ca ²⁺ in Nuclear Vesicle Fusion?	293
5.1. A Ca ²⁺ Store at the Nuclear Envelope	293
5.2. Generating Ca ²⁺ Signals in the Nucleus	293
5.3. Evidence for Nuclear Ca ²⁺ -Independent Nuclear Envelope Assembly	294
6. Nuclear Vesicle Fusion Requires Membrane-Associated Fusogenic Elements	295
6.1. Proteins Mediating Nuclear Membrane Fusion in Yeast Are Being Identified	295
6.2. Relevance of Kar Protein Homologues in Nuclear Vesicle Fusion	296
7. References	296

Chapter 8

Transactions at the Peroxisomal Membrane

Ben Distel, Ineke Braakman, Ype Elgersma, and Henk F. Tabak

1. Introduction	303
2. The Isolation of Yeast Mutants Disturbed in Peroxisome Function	305
3. Impermeability of the Peroxisomal Membrane	306
4. Import of Proteins into Peroxisomes	307
5. Formation of Peroxisomal Membranes	310
6. The ER to Peroxisome Connection	311
7. Do Peroxisomes Possess Unique Features?	314
8. Technical Shortcomings in the Peroxisome Field	315
9. Outlook	317
10. References	317

Chapter 9

Neurons, Chromaffin Cells and Membrane Fusion

Peter Partoens Dirk Slembrouck, Hilde De Baser,
 Peter F. T. Vaughan, Euido A. F. Van Dessel, Werner P. De Potter,
 and Albert R. Lagrou

1. Introduction	323
2. Biogenesis and Axonal Transport of LDV/Secretory Granules	326
3. Exocytosis from LDV/Secretory Granules	327
3.1. The Membrane Composition of Secretory Vesicles/LDV	327
3.2. The Role of the Cytoskeleton in Secretion from LDV	332
3.2.1. The Human Neuroblastoma SH-SY5Y as a Model to Study the Role of the Cytoskeleton in Secretion from LDV	332
3.2.2. Cytoskeletal and Vesicular Proteins and Exocytosis	334
3.2.3. Candidate Target Proteins for PKC Substrates	337
3.2.4. Control of Actin Dynamics	339
3.2.5. The Regulation of Cytoskeleton by PKC	340
3.2.6. MARCKS	343
3.2.7. GAP-43	346
3.2.8. Role of MARCKS in PKC Enhancement of Secretion in SH-SY5Y	347
3.3. Involvement of Isoprenylation/Carboxymethylation in Regulated Exocytosis	348
3.3.1. Role of Rab3 and Helper Proteins in Controlled Exocytosis	348
3.3.2. Processing of Proteins through Isoprenylation and Carboxymethylation	355
3.3.3. Regulatory Function of Protein Prenylation and Carboxymethylation in Exocytosis and Other Cellular Processes	358
4. Endocytosis of LDV/Secretory Vesicles	362
5. References	363

*Chapter 10***Reversibility in Fusion Protein Conformational Changes:
The Intriguing Case of Rhabdovirus-Induced Membrane Fusion**

Yves Gaudin

1. General Introduction	379
2. Metastability of the Native Viral Membrane Fusion Glycoprotein Is General	381
2.1. Influenza HA as the Model Fusogenic Glycoprotein	381
2.1.1. General	381
2.1.2. Low pH-Induced HA Conformational Change	381
2.2. Irreversibility of the Fusogenic Structural Transition Is a Common Feature of Viral Membrane Fusion	383
2.2.1. The Case of Fusogenic Glycoproteins Activated by Proteolytic Cleavage	383
2.2.2. The Case of Uncleaved Fusogenic Glycoproteins	384
3. The Rhabdovirus Exception	385
3.1. The Rhabdovirus Family	385
3.1.1. General	385
3.1.2. The Rhabdovirus Glycoprotein	385
3.2. Fusion Properties of Rhabdoviruses	387
3.3. Low pH-Induced Conformational Changes of Rhabdovirus G	388
3.3.1. One Protein, Three Conformational States	388
3.3.2. Identification of the Fusion Domain of Rhabdoviruses	391
3.3.3. Mutations Affecting G Conformational Changes	394
3.3.4. Role of the Fusion Inactive State	395
3.3.5. Other Differences between Rhabdoviral G and Influenza Virus HA Conformational Changes	397
4. Attempt to Reconcile the Data Obtained on Rhabdoviruses with those Obtained on other Viral Families	398
4.1. Existence of Reversible Steps in Fusogenic Glycoproteins Conformational Changes	398
4.2. How do Rhabdoviruses Overcome the High Energetic Barrier Encountered During Fusion?	398
4.3. Final Remarks	401
5. References	401

Chapter 11

**Specific Roles for Lipids in Virus Fusion and Exit:
Examples from the Alphaviruses**

Margaret Kielian, Prodyot K. Chatterjee, Don L. Gibbons,
and Yanping E. Lu

1. Introduction	409
2. The Alphavirus Lifecycle	410
2.1. Virus Structure and Assembly	411
2.2. Virus Entry and Fusion	413
2.2.1. Endocytic Entry and Low pH-Triggered Fusion	413
2.2.2. <i>In Vitro</i> Fusion with Liposomes	416
2.2.3. Conformational Changes in the Virus Spike during Membrane Fusion	416
2.3. Virus Exit Pathway and Requirements	419
3. The Role of Cholesterol in the Alphavirus Lifecycle	420
3.1. Role of Cholesterol in Fusion	420
3.1.1. <i>In Vitro</i> Cholesterol Requirements	420
3.1.2. <i>In Vivo</i> Cholesterol Requirements	422
3.2. Role of Cholesterol in Virus Exit	423
4. The Role of Sphingolipid in Alphavirus Fusion	424
4.1. <i>In Vitro</i> Requirement for Sphingolipid in Virus-Membrane Fusion	424
4.2. Structural Features of Fusion-Permissive Sphingolipids	424
5. Mechanisms of Cholesterol and Sphingolipid Requirements in Alphavirus Fusion and Exit	425
5.1. The Role of Cholesterol and Sphingolipid in Fusogenic Spike Protein Conformational Changes	425
5.2. Alphavirus Mutants with Reduced Cholesterol Requirements	427
5.2.1. Sequences Involved in the Alphavirus Cholesterol Requirement	427
5.2.1.1. Sequences Involved in the SFV Cholesterol Requirement	427
5.2.1.2. Sequences Involved in the SIN Cholesterol Requirement	430
5.2.2. Mechanism of the <i>ssf-3</i> Mutation	431
5.3. Mechanism of Cholesterol in Virus Exit	432
6. Role of Specific Lipids in the Entry and Exit of Other Pathogens	432

6.1. The Role of Cholesterol in Bacterial Toxin-Membrane Interactions	433
6.2. Other Viruses that May Require Specific Lipids	435
6.2.1. Human Immunodeficiency Virus	435
6.2.2. Mouse Hepatitis Virus	437
6.2.3. Ebola Virus	438
6.2.4. African Swine Fever Virus	439
6.2.5. Seadai virus	440
6.2.6. Role of Cholesterol in Transport of Influenza Hemagglutinin	441
6.3. Lipid Stalk Intermediates in Membrane Fusion Reactions	442
6.4. Cellular Fusion Proteins	443
7. Future Directions	445
8. References	446

Chapter 12

Fusion Mediated by the HIV-1 Envelope Protein

Carrie M. McManus and Robert W. Doms

1. Introduction	457
2. Viral Components of Fusion	458
2.1. Env	458
2.1.1. Gp120	458
2.1.2. Gp41	460
3. Cellular Components of Fusion	462
3.1. CD4	462
3.2. The Major HIV-1 Coreceptors	462
3.2.1. The Importance of CCR5 and CXCR4 <i>In Vitro</i> and <i>In Vivo</i>	464
3.3. Alternative HIV-1 Coreceptors	465
4. Envelope-Receptor Interactions	466
4.1. Env Determinants of Coreceptor Use	467
4.2. CCR5 Determinants	468
4.3. CXCR4 Determinants	469
4.4. Conformational Changes Resulting from Receptor Interactions	469
5. CD4-Independent Virus Infection	470
6. Implications for Therapeutic Intervention and Concluding Thoughts	471
7. References	472

Chapter 13

Sulfhydryl Involvement in Fusion Mechanisms

David Avram Sanders

1. Protein Thiols—An Introduction	483
1.1. Cysteine—A Special Residue	483
1.2. Oxidation and Reduction—Environment and Enzymatic Catalysis	484
1.3. Thiol and Disulfide Modification Reagents	486
2. Protein Thiols in Cellular Membrane Fusion	489
2.1. Identified Thiol-Reagent-Modified Proteins	489
2.1.1. <i>N</i> -ethylmaleimide-Sensitive Factor-NSF	489
2.1.2. Calpains	490
2.2. Experimental Systems with Thiol-Reagent- or Disulfide-Reagent-Modified Proteins of Unknown Identity	491
2.2.1. Frog Neuromuscular Junction	491
2.2.2. Mammalian Sperm-Egg Fusion	491
2.2.3. Insulin and Renin Secretion	492
2.2.4. Sea-Urchin Pronuclear Fusion during Fertilization	493
2.2.5. Sea-Urchin Egg Cortical Granule Exocytosis	493
2.2.6. Microsome Fusion	494
2.2.7. Endocytosis	495
3. Protein Thiols in Viral-Glycoprotein-Mediated Membrane Fusion and Virus Entry	496
3.1. Human Immunodeficiency Virus	496
3.2. Coronaviruses	497
3.3. Alphaviruses	498
3.4. Murine Leukemia Viruses	501
3.5. Other Retroviruses and Filoviruses	507
3.6. A Reconsideration of Alphavirus Entry	508
4. Conclusion	509
5. References	509
Index	515